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1. Introduction  
Nanoparticles and nanotechnology have been increasingly used in the field of cancer 
research, especially for the development of novel approaches for cancer detection and 
treatment (Majumdar, Peng et al. 2010; Davis, Chen et al. 2008). Magnetic iron oxide (IO, i.e. 
Fe3O4, Ǆ-Fe2O3) nanoparticles (NPs) are particularly attractive for the development of 
biomarker-targeted magnetic resonance imaging (MRI) contrast agents, drug delivery and 
novel therapeutic approaches, such as magnetic nanoparticle-enhanced hyperthermia. 
Given the unique pharmacokinetics of nanoparticles and their large surface areas to 
conjugate targeting ligands and load therapeutic agents, biodegradable IO nanoparticles 
have many advantages in targeted delivery of therapeutic and imaging agents. IO 
nanoparticles possess unique magnetic properties with strong shortening effects on 
transverse relaxation times, i.e., T2 and T*2, as well as longitudinal relaxation time, i.e., T1, at 
very low concentrations, resulting in contrast enhancement in MRI. Together with their 
biocompatibility and low toxicity, IO nanoparticles have been widely investigated for 
developing novel and biomarker-specific agents that can be applied for oncologic imaging 
with MRI. In addition, the detectable changes in MRI signals produced by drug-loaded IO 
nanoparticles provide the imaging capabilities of tracking drug delivery, estimating tissue 
drug levels and monitoring therapeutic response in vivo. With recent progress in 
nanosynthesis, bioengineering and imaging technology, IO nanoparticles are expected to 
serve as a novel platform that enables new approaches to targeted tumor imaging and 
therapy. In this chapter, we will review several aspects of magnetic nanoparticles, 
specifically IO nanoparticles, which are important to the development and applications of 
tumor-targeted imaging and therapy. An overview of general approaches for the 
preparation of targeted IO nanoparticles, including common synthesis methods, coating 
methodologies, selection of biological targeting ligands, and subsequent bioconjugation 
techniques, will be provided. Recent progress in the development of IO nanoparticles for 
tumor imaging and anti-cancer drug delivery, as well as the outstanding challenges to these 
approaches, will be discussed. 
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2. Preparation of IO nanoparticles 
Typical IO nanoparticles are prepared through bottom-up strategies, including 
coprecipitation, microemulsion approaches, hydrothermal processing and thermal 
decomposition (Figure 1) (Gupta and Gupta 2005; Laurent, Forge et al. 2008; Laurent, 
Boutry et al. 2009; Xie, Huang et al. 2009). The advantages and disadvantages of these 
conventional nanofabrication techniques are important and need to be taken into account in 
designing and developing a nanoparticle construct for specific cancer models and 
applications. 
 
 
Fig. 1. (A) Fe3O4 NPs synthesized by coprecipitation method, the scale bar is 30 nm;  
(B) Fe3O4 NPs prepared by thermal decomposition of iron oleate Fe(OA)3.  
(Reproduced with permission from Kang, Y. S., S. Risbud, et al. (1996).  
"Synthesis and characterization of nanometer-size Fe3O4 and gamma-Fe2O3 particles." 
Chemistry of Materials 8(9): 2209-2211and Park, J., K. J. An, et al. (2004).  
"Ultra-large-scale syntheses of monodisperse nanocrystals." Nature Materials 3(12):  
891-895. 
Coprecipitation is the most commonly used approach due to its simplicity and scalability. It 
features coprecipitating Fe(II) and Fe(III) salts in the aqueous solution by adding bases, 
usually NH4OH or NaOH (Massart 1981). The resulting IO nanoparticles are affected by 
many synthetic parameters, such as pH value, concentrations of reactants, reaction 
temperature etc. In addition, small molecules and amphiphilic polymeric molecules are 
introduced to enhance the ionic strength of the medium, protect the formed nanoparticles 
from further growth, and stabilize the colloid fluid (Kang, Risbud et al. 1996; Vayssieres, 
Chaneac et al. 1998). Though this method suffers from broad size distribution and poor 
crystallinity, it is widely used in fabricating IO-based MRI contrast agents (such as dextran-
coated IO nanoparticles), because of its simplicity and high-throughput (Sonvico, Mornet et 
al. 2005; Muller, Skepper et al. 2007; Hong, Feng et al. 2008; Lee, Li et al. 2008; Agarwal, 
Gupta et al. 2009; Nath, Kaittanis et al. 2009). A modification of the coprecipitation method 
is the reverse micelle method, in which the Fe(II) and Fe(III) salts are precipitated with bases 
in microemulsion (water-in oil) droplets stabilized by surfactant. The final size and shape of 
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the nanoparticles can be precisely tuned through adjusting the surfactant concentration or 
the reactants concentration (Santra, Tapec et al. 2001; Zhou, Wang et al. 2001; Lee, Lee et al. 
2005; Hong, Feng et al. 2009). The disadvantages of this method are its low yield and poor 
crystallinity of the product, which limit its practical use. A hydrothermal method is also 
considered a promising synthetic approach for IO nanoparticles towards biomedical 
applications, which is performed in a sealed autoclave with high temperature (above solvent 
boiling points) and autogenous high pressure, resulting in nanoparticles with narrow size 
distribution (Daou, Pourroy et al. 2006; Liang, Wang et al. 2006; Taniguchi, Nakagawa et al. 
2009). 
High quality IO nanoparticles with perfect monodispersity and high crystallinity can be 
fabricated by the state of the art thermal decomposition method. Iron precursors, usually 
organometallic compounds or metal salts (e.g. Fe(acac)3, Fe(CO)5, and Fe(OA)3), are 
decomposed in refluxing organic solvent in the presence of surfactant (e.g. oleic acid, and 
oleic amine) (Hyeon, Lee et al. 2001; Sun and Zeng 2002; Park, An et al. 2004; Sun, Zeng et al. 
2004; Park, Lee et al. 2005; Lee, Huh et al. 2007). In this method, the size and morphology of 
the nanoparticles can be controlled by modulating the temperature, reaction time, surfactant 
concentration and type of solvent. Using smaller nanoparticles as growth seed, Hyeon and 
co-workers prepared 1-nm IO nanoparticles through additional thermal decomposition 
growth (Park, Lee et al. 2005). The obtained nanoparticles are usually hydrophobic, 
dispersible in organic solvent, which requires further phase transfer procedures to make 
them water-soluble. Recently, several studies have demonstrated that directly thermal 
decomposing iron precursors in strong polar solvents (e.g. DMF, 2-pyrrolidone) resulted in 
hydrophilic IO nanoparticles, which could be readily dispersed in water, as preferred in 
biomedical applications (Liu, Xu et al. 2005; Neuwelt, Varallyay et al. 2007; Wan, Cai et al. 
2007). 
Coating materials play an important role in stabilizing aqueous IO nanoparticle suspensions 
as well as further functionalization. Appropriate coating materials can effectively render the 
water solubility of the IO nanoparticles and improve their stability in physiological 
conditions. The coating of IO nanoparticles can be achieved through two general 
approaches: ligand addition and ligand exchange (Gupta, Gupta 2005; Xie, Huang et al. 
2009). In ligand addition, the stabilizing agents can physically adsorb on the IO nanoparticle 
surface as a result of various physico-chemical interactions, including electrostatic 
interaction, hydrophobic interaction, and hydrogen bonding, etc. Besides physical 
adsorption, coating materials with abundant hydroxyl, carboxyl, and amino groups can 
readily and steadily absorb on the surface of the bare IO nanoparticle core, as the active 
functional groups are capable of coordinating with the iron atoms on the surface to form 
complexes (Gu, Schmitt et al. 1995). Even for nanoparticles with pre-existing hydrophobic 
coating, newly added amphiphilic agents could also stick on the surface physically or 
chemically to complete phase transfer. Various materials, including natural organic 
materials (e.g. dextran, starch, alginate, chitosan, phospholipids, proteins etc.) (Kim, 
Mikhaylova et al. 2003; Peng, Hidajat et al. 2004; Kumagai, Imai et al. 2007; Muller, Skepper 
et al. 2007; Nath, Kaittanis et al. 2009; Zhao, Wang et al. 2009) and synthetic polymers (e.g. 
polyethylene glycol (PEG), poly(acrylic acid) (PAA), polyvinylpyrrolidone (PVP), poly(vinyl 
alcohol) (PVA), poly(methylacrylic acid) (PMAA), poly(lactic acid) (PLA), 
polyethyleneimine (PEI), and block copolymers etc.) (Lutz, Stiller et al. 2006; Narain, 
Gonzales et al. 2007; Mahmoudi, Simchi et al. 2008; Hong, Feng et al. 2009; Yang, Mao et al. 
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2009; Yang, Peng et al. 2009; Hadjipanayis, Machaidze et al. 2010; Huang, Bu et al. 2010; 
Namgung, Singha et al. 2010; Vigor, Kyrtatos et al. 2010; Wang, Neoh et al. 2010) have been 
demonstrated to successfully coat the surface of IO nanoparticles through ligand addition. 
Alternatively, ligand exchange refers to the approach of replacing the pre-existing coating 
ligands with new, higher affinity ones. One such example is that of dopamine (DOP)-based 
molecules, which can can substitute the original oleic acid molecules on the surface of IO 
nanoparticles, as the bidentate enediol of DOP coordinates with iron atoms forming strong 
bonds (Huang, Xie et al. 2010; Xie, Wang et al. 2010). Dimercaptosuccinic acid (DMSA) and 
polyorganosiloxane could also replace the original organic coating by forming chelate 
bonding (De Palma, Peeters et al. 2007; Lee, Huh et al. 2007; Chen, Wang et al. 2010). After 
ligand addition and ligand exchange, surface-initiated crosslinking might be performed for 
further coating stabilization, yielding nanoparticles with great stability against 
agglomeration in the physiological environment (Lattuada and Hatton 2007; Chen, Wang et 
al. 2010). 
3. Surface modification and functionalization of IO nanoparticles 
Surface modification and functionalization play critical roles in the development of any 
nanoparticle platform for biomedical applications. However, the capacity of the 
functionalization may be highly dependent on the diversity and chemical reactivity of the 
surface coating materials as well as the functional moieties used for biological interactions 
and targeting. Commonly used functional groups, i.e., carboxyl -COOH, amino -NH2 and 
thiol –SH groups, are ideal for covalent conjugation of payload molecules or moieties. 
However, there is an increased application of non-covalent interactions, such as 
hydrophobic and electrostatic forces, to incorporate the payload molecules.  
Recently developed theranostics IO nanoparticles, i.e., multifunctional nanoparticles capable 
of both diagnostic imaging and delivery of therapeutics, often consist of small molecules 
(e.g, chemotherapy drugs, optical dyes) or biologics (e.g., antibodies, peptides, nucleic acids) 
to achieve effective targeted imaging and drug delivery. These functional moieties have 
high affinity and specificity for biomarkers, such as cell surface receptors or cellular 
proteins, which can enhance specific accumulation of IO nanoparticles at the target site. 
Major techniques for the functionalization of IO nanoparticles include the selection of 
biomarker-targeting ligands and the conjugation of targeting ligands on the nanoparticle 
surface (Figure 2). Targeting moieties can be obtained via screening of synthetic 
combinatorial libraries and subsequent amplification through an in vitro selection process 
(Yang, Peng et al. 2009; Hadjipanayis, Machaidze et al. 2010; Lee, Yigit et al. 2010). The 
selection process usually starts with a random moieties library generated through chemical 
synthesis, and polymerase chain reaction (PCR) amplification or cloning of the identified 
targeting moiety through transfected/infected cells. Purification is acheived by incubating 
the library with target molecules or target cells, so that the high affinity moieties can be 
captured, separated from those unbound moieties, and eluted from the target molecule or 
cells. In addition, counter selection might be performed to enhance the purity of the isolated 
targeting moiety. Amplification via PCR or cloning throguh transfected/infected cells will 
result in new libraries of targeting moieties enriched with higher affinity ones. The selection 
process may be repeated for several rounds, and the targeting moieties with the highest 
affinity to the target can be obtained for further functionalization of magnetic IO 
nanoparticles. 
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Fig. 2. (A) A schematic example of the selection process of targeting moieties. (B) 
Conjugation of IO nanoparticles with targeting ligands through maleimide reactions. 
An active targeting approach in nanomedicine involves the direct conjugation of targeting 
ligands to the surface of nanoparticles rather than adsorption encapsulation. A variety of 
bioconjugation reactions have been developed by the incorporation of functional groups 
(e.g. carboxyl group, and amino group, thiol group) at the IO nanoparticle surface and in the 
targeting ligands. Besides affinity interactions, click chemistry, and streptavidin biotin 
reactions (Yang, Mao et al. 2009; Cutler, Zheng et al. 2010; Vigor, Kyrtatos et al. 2010), 
bioconjugation can be achieved by using linker molecules with carboxyl-, amine- or thiol-
reactive groups, such as glutaraldehyde, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC), N-hydroxysuccinimide (NHS), succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC), N-succinimidyl-3-(2-pyridyldithio)-
propionate (SPDP), etc. (Lee, Huh et al. 2007; Lee, Li et al. 2008; Bi, Zhang et al. 2009; Yang, 
Mao et al. 2009; Yang, Peng et al. 2009; Hadjipanayis, Machaidze et al. 2010; Kumar, Yigit et 
al. 2010; Vigor, Kyrtatos et al. 2010; Yang, Park et al. 2010). For example, Yang et al. 
conjugated amphiphilic polymer-coated IO nanoparticles with amino-terminal fragment 
peptides via cross-linking of carboxyl groups to amino side groups through an EDC/NHS 
approach (Yang, Peng et al. 2009). The well developed bioconjugation methodologies 
advance the surface engineering of IO nanoparticles and expand the functionalities of IO 
nanoparticles. 
4. Recent progress using IO nanoparticles for tumor imaging and therapy 
With the emphasis on personalized medicine in future clinical oncology practices, the 
potential applications of biomarker-targeted imaging and drug delivery approaches are well 
recognized.  Tumor-targeted IO nanoparticles that are highly sensitive imaging probes and 
effective carriers of therapeutic agents are the logical choice of a platform for future clinical 
development. Increasing evidence indicates that the selective delivery of nanoparticle 
therapeutic agents into a tumor mass can minimize toxicity to normal tissues and maximize 
bioavailability and cell killing effects of cytotoxic agents. This effect is mainly attributed to 
changes in tissue distribution and pharmacokinetics of drugs. Furthermore, IO nanoparticle-
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drugs can accumulate to reach high concentrations in certain solid tumors than free drugs 
via the enhanced permeability and retention effect (EPR). However, the EPR facilitates only 
a certain level of tumor targeting, while actively tumor-targeted IO nanoparticles may 
further increase the local concentration of drug or change the intracellular biodistribution 
within the tumor via receptor-mediated internalization.  
4.1 Targeted IO nanoparticles for tumor imaging 
Passive targeting of tumors with  IO nanoparticles via the EPR effect plays an important role 
in the delivery of IO nanoparticles in vivo and can be used for tumor imaging. However, the 
biodistribution of such IO nanoparticles is non-specific, resulting in insufficient 
concentrations at the tumor site, and thus low sensitivity and specificity. The development 
of tumor-targeted IO nanoparticles that are highly sensitive and specific imaging probes 
may overcome such problems. 
Various genetic alterations and cellular abnormalities have been found to be particularly 
distributed in tumors rather than in normal tissues. Such differences between normal and 
tumor cells provide a great opportunity for engineering tumor-targeted IO imaging probes. 
Antibodies, peptides and small molecules targeting related receptors on the surface of 
tumor cells can be conjugated to the surface of IO nanoparticles to enhance their imaging 
sensitivity and specificity. Many studies have reported using targeted IO nanoparticles for 
tumor imaging in vitro and in vivo, and such nanoparticles may have the potential to be 
used in the clinic in the near future. 
Antibodies are widely used for engineering tumor targeted IO nanoparticles for in vivo 
tumor imaging due to their high specificity. The conjugation of antibodies to IO 
nanoparticles can maintain both the properties of the antibody and the magnetic particles. 
Monoclonal antibody-targeted IO nanoparticles have been well studied in vivo (Artemov, 
Mori et al. 2003; Serda, Adolphi et al. 2007; Kou, Wang et al. 2008; Chen, Cheng et al. 
2009).  
One well-known tumor target, the human epidermal growth factor receptor 2 (Her-2/neu 
receptor), has been found overexpressed in many different kinds of cancer such as breast, 
ovarian, and stomach cancer. Yang et al (Yang, Park et al. 2010) conjugated the HER2/neu 
antibody (Ab) to poly(amino acid)-coated IO nanoparticles (PAION), which have abundant 
amine groups on the surface. After conjungation, the diameter of PAION-Ab was 31.1 ± 7.8 
nm, and the zeta-potential was negative (−12.93 ± 0.86 mV) due to the shield of amine 
groups by conjugated Her-2 antibodies.  Bradford protein assay indicates that there are 
about 8 HER2/neu antibodies on each PAION. The T2 relaxation times showed a significant 
difference between the PAION-Ab-treated (37.7 ms) and untreated cells (79.9 ms) in positive 
groups (SKBR-3 cells, overexpressing HER-2), while no significant difference was founded 
in T2-weighted MR images of negative groups (H520 cells, HER-2 negative). The results 
demonstrated that HER2/neu antibody-conjugated PAION have specific targeting ability for 
HER2/neu receptors. Such HER2/neu antibody-conjugated PAION with high stability and 
sensitivity have potential to be used as an MR contrast agent for the detection of HER2/neu 
positive breast cancer cells. Herceptin, a well-known antibody against the HER2/neu 
receptor, which has been used in the clinic for many years, can also be conjugated to the IO 
nanoparticles for breast cancer imaging. Using such herceptin-IO nanoparticles, small 
tumors of only 50 mg in weight can be detected by MRI (Lee, Huh et al. 2007).  
However, the relatively large size of intact antibodies limits their efficient conjugation because 
of steric effects. The specificity of antibody-conjugated IO nanoparticles may also decrease due 
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to the interaction of antibody with Fc receptors on normal tissues. In addition, the expensive 
cost of intact antibodies further limits the application of antibody-targeted IO nanoparticles. 
Recently, more and more studies have reported engineering targeted IO nanoparticles using 
single chain antibodies (scFv) or peptides with small molecular weight and size. Compared 
with intact antibodies, there are many advantages of using scFv as tumor targeting ligands, 1) 
relatively small molecular weight and size; 2) no loss of antigen binding capacity; 3) no 
immune responses due to lack of Fc constant domain; 4) low cost and easily obtained.   
The epidermal growth factor receptor (EGFR) signaling pathway is involved in the regulation 
of cell proliferation, survival, and differentiation, and it has been found overexpressed in 
many different kinds of cancer such as breast, ovarian, lung, head and neck cancer. By using 
a high-affinity single-chain anti-EGFR antibody (scFvB10, KD = 3.36 × 10−9 M), Yang et al. has 
developed a EGFR-targeted amphiphilic triblock polymer coated IO nanoparticle for in vivo 
tumor imaging (Yang, Mao et al. 2009) (Figure 3). ScFvEGFR was conjugated to IO 
nanoparticles by crosslinking carboxyl groups to amino groups of the ScFvEGFR proteins 
mediated by ethyl-3-dimethyl amino propyl carbodiimide (EDAC). The in vitro results 
showed that the ScFvEGFR IO nanoparticles specifically bind to EGFR, which was 
demonstrated by Prussian blue staining and MRI (Figure 4). The EGFR-targeted or non-
targeted IO nanoparticles were administrated via the tail vein to nude mice bearing 
orthotopical human pancreatic cancer xenograft. The results showed that the ScFvEGFR-IO 
nanoparticles could selectively accumulate within the pancreatic tumors, which was 
evidenced by a decrease in MRI signal in the tumor site and confirmed by histological 
examination of the pancreatic tissue, while non-targeted IO nanoparticles did not cause MRI 
signal changes in tumor. 
A high affinity scFv reactive to carcinoembryonic antigen (CEA), sm3E, was covalently 
conjugated to superparamagnetic iron oxide nanoparticles (SPIONs), and the functionalized 
SPIONs could bind specifically to CEA while unmodified SPIONs did not show any binding 
ability. The ability of the targeted-SPIONs to specifically target and image CEA was further 
demonstrated by using the colorectal cancer cell line LS174T (CEA-expressing) and adherent 
melanoma cell line A375M (CEA negative). MR images showed 57% reduction in T2 values 
compared with the 11% reduction induced by non-targeted SPIONs (Vigor, Kyrtatos et al. 
2010). 
Peptides that target specific receptors on the tumor cell surface can be used for engineering 
targeted IO nanoparticles for tumor imaging due to their small size and molecular weight. 
The urokinase plasminogen activator receptor (uPAR) is expressed in many different human 
cancers, and may play important roles in the tumor metastasis. The amino-terminal 
fragment (ATF) of urokinase plasminogen activator (uPA) can bind to uPAR on the cell 
surface, thus the ATF peptide is ideal for constructing uPAR-targeted IO nanoparticles for in 
vivo tumor imaging. Yang et al. purified the ATF peptide and conjugated it to amphiphilic 
polymer-coated IO nanoparticles (Yang, Mao et al. 2009). These uPAR-targeted IO 
nanoparticles showed selective accumulation at the tumor mass in orthotopical xenografted 
human pancreatic cancer model. More importantly, such uPAR-targeted IO nanoparticles 
could be internalized by both uPAR-expressing tumor cells and tumor-associated stromal 
cells, to further increase the amount and retention of the IO nanoparticles in a tumor mass, 
which increased the sensitivity of tumor detection by MRI. Pancreatic tumors as small as 1 
mm3 could be detected by a 3T clinical capable MRI scanner using the targeted IO 
nanoparticles. After labeling the ATF peptide with the near infrared (NIR) dye Cy5.5, the 
targeted IO nanoparticles enabled the detection of  a 0.5 mm3 intraperitoneal pancreatic 
cancer lesion by NIR optical imaging. Further study showed that NIR optical imaging 
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detected tumor cell implants with only 1 × 104 tumor cells while MRI detected tumor cell 
grafts containing 1 × 105 labeled cells (Figure 5). 
 
 
Fig. 3. ScFvEGFR-conjugated IO nanoparticles show high  specificity to EGFR-overexpressing 
tumor cells and induce MRI signal changes in IO nanoparticle-bound tumor cells in vitro. A) 
ScFvEGFR-IO nanoparticle construct consists of uniform IO nanoparticles (10 nm core size) 
coated with amphiphilic copolymers modified with short PEG chains. ScFvEGFR proteins 
were conjugated to the IO nanoparticles mediated by EDAC. B) Prussian blue staining 
confirmed the specific binding of the ScFvEGFR-IO nanoparticles to tumor cells with EGFR 
overexpression . C) T2 weighted MRI and T2 relaxometry mapping showed significant 
decreases in MRI signals and T2 relaxation times in the cells bound with ScFvEGFR-IO 
nanoparticles but not with GFP-IO nanoparticles or bare IO nanoparticles.  MDA-MB-231 
breast cancer cells and MIA PaCa-2 pancreatic cancer cells have different levels of EGFR 
expression and different levels of T2 weighted contrast. A low T2 value correlates with a higher 
iron concentration (red color), indicating higher level of specific binding of ScFvEGFR-IO 
nanoparticles to tumor cells. D) Multi-echo T2 weighted fast spin echo imaging further 
confirmed the fastest T2 value drop in MDA-MB-231 cells after incubation with ScFvEGFR-IO 
but not with control GFP-IO nanoparticles. Reproduced with permission from Yang, L., H. 
Mao, et al. (2009). "Single chain epidermal growth factor receptor antibody conjugated 
nanoparticles for in vivo tumor targeting and imaging." Small 5(2): 235-43. 
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Fig. 4. Examination of target specificity of ScFvEGFR-IO nanoparticles by MRI using an 
orthotopic human pancreatic xenograft model, the areas of the pancreatic tumor were marked 
as pink dash-lined circle. Right is the picture of tumor and spleen tissues, showing sizes and 
locations of two intra-pancreatic tumor lesions (arrows) that correspond with the tumor 
images of MRI. Reproduced with permission from Yang, L., H. Mao, et al. (2009). "Single chain 
epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor 
targeting and imaging." Small 5(2): 235-43. 
The approach of using optically sensitive small dye molecules along with MRI-capable IO 
nanoparticles not only provides a potential multi-modal imaging capability for future 
application but also a way to validate and track the magnetic IO nanoparticles to investigate 
tumor targeting and biodistribution of nanoparticle constructs in animal models.   
Underglycosylated mucin-1 antigen (uMUC-1) is overexpressed in more than 50% of all 
human cancers and is located on the surface of tumor cells. The EPPT1 peptide, which is 
able to specifically bind to uMUC-1, has been synthesized and used by Moore et al. to 
fabricate uMUC-1-targeted superparamagnetic IO nanoparticles with dextran coating, their 
results showed that such targeted CLIO nanoparticles could induce a significant T2 signal 
reduction in uMUC-1-positive LS174T tumors compared with that of uMUC-1-negative U87 
tumors in vivo (Moore, Medarova et al. 2004). 
The luteinizing hormone releasing hormone (LHRH) (Chatzistamou, Schally et al. 2000) is a 
decapeptide, and more than half of human breast cancers express binding sites for receptors 
for LHRH. Leuschner et al synthesized LHRH-SPIO nanoparticles, and both in vitro and in 
vivo data showed that the IO nanoparticles selectively accumulated in both primary tumor 
cells and metastatic cells. The LHRH-conjugated SPIO nanoparticles may have potential to 
be used for detecting metastatic breast cancer cells in vivo in the future (Leuschner, Kumar et 
al. 2006).  
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Fig. 5. Examination of sensitivity of in vivo tumor imaging. (A) uPAR-targeted MRI of an 
orthotopic pancreatic cancer. Tumor is marked as pink dotted circle. Prussian blue staining 
revealed the presence of IO nanoparticles in the tumor lesion with strong staining in tumor 
stromal areas. (B) NIR optical imaging and (C) MRI of injected labeled cells and nonlabeled 
cells in mouse pancreas. Reproduced with permission from Yang, L., H. Mao, et al. (2009). 
"Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional 
nanoparticles." Gastroenterology 136(5): 1514-25. 
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In contrast, cost effective but high affinity small molecule targeting moities are not widely 
available or well tested. One exception is folic acid (FA), which targets the folate receptor, 
which is overexpressed on the surface of many human tumor cells and can thus be used as a 
target for tumor imaging. The vitamin FA has low molecular weight and has been widely 
studied as a targeting ligand. There are many advantages of using FA as a targeting ligand 
for synthesizing IO nanoparticles, 1) high binding affinity for its receptor (Kd = 10−10 M), 2) 
low cost and easily obtained, 3) easy to be conjugated with the imaging agents, 4) lack of 
immunogenicity (Low, Henne et al. 2008). Sun et al constructed the FA-IO-nanoparticles, the 
in vitro experiments showed that FR-positive HeLa cells could uptake1.410 pg iron per cell 
after incubated with FR-targeted IO nanoparticles for 4 hrs, which was 12-fold higher than 
those cultured with non-targeted IO nanoparticles, and the increased internalization could 
be inhibited by increasing free FA concentration, and such targeting specificity of the FR-
targeted IO nanoparticles could be further demonstrated by using FR-negative Human 
osteosarcoma MG-63 cells. The T2-weighted MR phantom images of HeLa cells cultured 
with FR-targeted IO nanoparticles showed significantly lower T2 values (23.5–14.2 ms) than 
those incubated with non-targeted IO nanoparticles (80.2–49.3 ms)(Sun, Sze et al. 2006). 
Another study also showed FA-targeted IO nanoparticles could selectively accumulate in 
human nasopharyngeal epidermoid carcinoma (KB) cells both in vitro and in vivo, which 
resulted in significant MRI signal changes (Chen, Gu et al. 2007).  
Given the concerns regarding the delivery of fairly large nanoparticle constructs directly 
into the tumor, targeted imaging and drug delivery into the tumor vasculture, which is 
often associated with tumor angiogenesis, appears to be a feasible approach.  Angiogenesis 
is essential for the development of tumors. As a marker of angiogenesis, the v3 integrin 
locates on the surface of the tumor vessels and can be directly targeted via blood. The Arg-
Gly-Asp (RGD) peptide, which can bind to the ǂvǃ3 integrin receptor, has been well studied 
as a tumor vessel-targeted ligand. One study using RGD-USPIO nanoparticles for tumor 
vessel imaging showed that RGD-USPIO nanoparticles could target to the tumor vessels and 
resulted in a change in T2 relaxation detected at the field strength of 1.5 T with a clinical MRI 
scanner, and the signal changes were correlated to the ǂvǃ3 integrin expression level (Zhang, 
Jugold et al. 2007).  
On the other hand, targeted delivery of biomarker-specific nanoparticle constructs to brain 
tumors needs to overcome the challenge of penatrating the intrinsic blood-brain barrier. 
Efforts have been made to identify the appropriate design of nanoparticle constructs for 
targeting brain tumors. It has been reported that matrix metalloproteinase-2 (MMP-2) is 
overexpressed in gliomas and other related cancers, and facilitates cancer invasion 
(Soroceanu, Gillespie et al. 1998; Deshane, Garner et al. 2003; Veiseh, Gabikian et al. 2007). 
The chlorotoxin (Cltx) is a small peptide (36-amino acid) which can recognize and bind to 
the MMP-2 endopeptidase,  one study showed that Cltx-conjugated IO nanoparticles could 
be taken up in 9L glioma cells at significantly higher concentrations than that of their non-
targeted counterpart, which further resulted in a significant difference in R2(1/T2) relaxivity 
between Cltx-targeted IO nanoparticle- (5.20 mm-1s-1) and non-targeted IO nanoparticle- 
(0.22 mm-1s-1 ) treated tumor cells, and such R2 change was also observed by MRI in vivo 
(Sun, Veiseh et al. 2008). One alternative and potential solution for overcoming the blood-
brain barrier to deliver therapeutic IO nanoparticles is the use of conventional enhanced 
delivery, in which a magnetic IO nanoparticle suspension can be slowly infused into the 
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tumor site via a minimally invasive procedure (Hadjipanayis, C. G., R. Machaidze, et al. 
(2010)). 
There are still many issues that need to be addressed in the study of IO nanoparticles for 
tumor imaging, and which must be throughly investigated in future studies. These include: 
1) the optimal coating of the IO nanoparticles, which may avoid non-specific binding to 
normal cells, prolong the blood circulation time, and make the IO nanoparticles more stable 
in physiological conditions; 2) quantification of the density of targeted ligand on the surface 
of IO nanoparticles, which may affect the binding and internalization of IO nanoparticles, as 
well as their in vivo biodistribution; 3) the long-term fate and toxicity of targeted IO 
nanoparticles in vivo. Until now, most tumor-targeted IO nanoparticles have only been 
applied in vitro or in small animal models for tumor imaging, and are not yet ready for 
clinical use. The development of tumor-targeted IO nanoparticles with high specificity and 
sensitivity in vivo for early stage detection of tumors, monitoring of tumor metastasis and 
response to therapy is greatly needed. 
4.2 Tumor-targeted IO nanoparticles as selective drug delivery vehicles 
The selective delivery of therapeutic agents into a tumor mass may enhance the antitumor 
efficacy while minimizing toxicity to normal tissues (Brigger, Dubernet et al. 2002; Maillard, 
Ameller et al. 2005; Shenoy, Little et al. 2005; Bae, Diezi et al. 2007; Gang, Park et al. 2007; 
Lee, Chang et al. 2007). While the delivery of small molecule drugs to the tumor is often 
limited by fast secretion, drug solubility and low intra-tumor accumulation, nanoparticle 
delivery vehicles can alter the pharmacokinetics and tissue distribution profile in favor of 
tumor specific accumulation. It is widely considered that nanoparticle-drugs can accumulate 
to higher concentrations in certain solid tumors than free drugs via the enhanced 
permeability and retention effect (EPR). In addition, actively tumor-targeted nanoparticles 
may further increase the local concentration of drug or change the intracellular 
biodistribution within the tumor via receptor-mediated internalization. With magnetic IO 
nanoparticles, the imaging capability allows for monitoring and potential quantification of 
the IO nanoparticle-drug complex in vivo with MRI. 
Therapeutic entities, such as small molecular drugs, peptides, proteins and nucleic acids, 
can be incorporated in the IO nanoparticles through either loading on the surface layer or 
trapping within the nanoparticles themselves. When delivered to the target site, the 
loaded drugs are usually released by 1) diffusing; 2) vehicle rupture or dissolution; 3) 
endocystosis of the conjugations; 4) pH-sensitive dissociation, etc. Such delivery carriers 
have many advantages, including 1) water-soluble; 2) low toxic or nontoxic; 3) 
biocompatible and biodegradable; 4) long blood retention time; 5) capacity for further 
modification. Futhermore, these therapeutic IO conjugations enable the simultaneous 
estimation of tissue drug levels and monitoring of therapeutic response (Lanza, Winter et 
al. 2004; Atri 2006). 
Conventional anti-cancer agents, such as doxorubicin, cisplatin, and methotrexate, have 
been conjugated with tumor-targeted IO nanoparticles to achieve effective delivery. 
Recently Yang et al (Yang, Grailer et al. 2010) developed folate receptor-targeted IO 
nanoparticles to deliver doxorubicin (DOX) to tumor cells. As shown in Figure 6, the 
hydrophillic IO nanoparticles were encapsulated in the multifunctional polymer vesicles in 
aqueous solution, the long hydrophilic PEG segments bearing the FA targeting ligand 
located in outer layers, while the short hydrophilic PEG segments bearing the acrylate 
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groups located in inner layers. The anticancer drug (DOX) was conjugated onto the 
hydrophobic polyglutamate polymer segments via an acid-cleavable hydrazone bond, and 
could release at low pH value. The loading efficacy of DOX was about 14 wt %. The  
FA-conjugated SPIO/DOX-loaded vesicles demonstrated higher cellular uptake  
and cytotoxicity compared with FA-free vesicles due to folate receptor-mediated 
endocytosis. 
 
 
 
Fig. 6. Synthetic scheme of the amphiphilic triblock copolymers and the preparation  
process of the SPIO/DOX-loaded vesicles with cross-linked inner hydrophilic PEG layers. 
Reproduced with permission from Yang, X., J. J. Grailer, et al. (2010). "Multifunctional  
stable and pH-responsive polymer vesicles formed by heterofunctional triblock copolymer 
for targeted anticancer drug delivery and ultrasensitive MR imaging." ACS Nano 4(11): 
6805-17. 
Cisplatin (DDP) is one of the most widely used chemotherapy drugs in the treatment of 
cancers,  including head and neck, testicular, bladder, ovarian,  and  non-small lung cancer. 
However, the major dose limiting toxicity of DDP is cumulative nephrotoxicity; severe and 
irreversible damage to the kidney will occur in about 1/3 of patients who receive DDP 
treatment. The selective delivery of DDP to tumor cells would significantly reduce drug 
toxicity, improving its therapeutic index. Recently, IO nanoparticles have been used as DDP 
carriers for targeted therapeutic applications. Sun’s group (Cheng, Peng et al. 2009) reported 
DDP porous could be loaded into PEGylated hollow NPs (PHNPs) of Fe3O4 by using the 
nanoprecipitation method (Figure 7), which resulted in 25% loading efficacy. Herceptin was 
covalently attached to the amine-reactive groups on the Pt-PHNP surface, and such 
conjugation did not change the Herceptin activity. Results showed that DDP could release 
from the Her-Pt-PHNPs in the acidic endosomes or lysosomes after internalization by cells, 
and could significantly increase the cytotoxicity of DDP.  
Methotrexate (MTX) can be used as both a targeting molecule for folate receptor (FR) and a 
therapeutic agent for cancer cells overexpressing FR on their surface. Its  carboxyl end 
groups provide the opportunity to be conjugated on the IO nanoparticles with amine 
groups. Kohler et al. have demonstrated that the uptake of MTX-IO nanoparticles by FR-
overexpressing cancer cells was significant higher than that of FR-negative control cells. This 
system showed high drug loading efficiency, about 418 MTX molecules could be loaded 
onto each IO nanoparticle with a core size of 10 nm diameter. Loaded MTX was only 
released inside the lysosomes at low pH condition after internalization by the targeted cells, 
and the drug delivery system could be monitored in vivo by MRI in real-time (Kohler, Sun 
et al. 2005).  
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Fig. 7. Schematic illustration of simultaneous surfactant exchange and cisplatin loading into 
a PHNP and functionalization of this PHNP with Herceptin. Reproduced with permission 
from Cheng, K., S. Peng, et al. (2009). "Porous hollow Fe3O4 nanoparticles for targeted 
delivery and controlled release of cisplatin." J Am Chem Soc 131(30): 10637-44. 
RNA interference (RNAi) has become a promising molecular therapeutic tool due to its high 
specificity. One of the big challenges for its in vivo application is that small interfering RNA 
(siRNA) cannot reach the target tissue at sufficient concentrations due to RNase degradation 
and inefficient translocation across the cell membrane. IO nanoparticles are expected to be 
applicable for delivering siRNA and monitoring the efficacy of therapy because of their 
unique characteristics as described above. It has been reported that BIRC5 could encode the 
antiapoptotic survivin proto-oncogene, and can be used as a good target for tumor therapy. 
The knockdown of BIRC5 by RNAi may mediate a therapeutic effect by inducing 
necrotic/apoptotic tumor cell death. Kumar et al (Kumar, Yigit et al. 2010) synthesized a 
novel tumor-targeted nanodrug (MN-EPPT-siBIRC5), which consists of 1) peptides (EPPT) 
that specifically target the antigen uMUC-1; 2) IO nanoparticles; 3) the NIR dye, Cy 5.5 and 
4) siRNA that targets the tumor-specific antiapoptotic gene BIRC5 (Figure 8). Systemic 
delivery of MN-EPPT-siBIRC5 to nude mice bearing human breast adenocarcinoma tumors 
showed significant decrease of T2 relaxation time of the tumor, which remained significantly 
lower than the preinjection values over time, suggesting that the concentration of nanodrug 
within the tumor tissue could be maintained. While this demonstrated that it is feasible to 
follow the accumulation and retention of drug-IO nanoparticles in vivo with MRI, the in 
vivo data also showed that MN-EPPT-siBIRC5 therapy can led to a 2-fold decrease in the 
tumor growth rate compared with the MN-EPPT-siSCR-treated group. The efficacy of MN-
EPPT-siBIRC5 in the breast tumors was evaluated by H&E staining and TUNEL assay, 
which showed a 5-fold increase in the fraction of apoptotic nuclei in tumors in MN-EPPT-
siBIRC5 treated mice via the MN-EPPT-siSCR group. 
Tumor-targeted IO nanoparticles can also be used to “rescue” some anticancer drugs which 
show severe toxicity, low solubility or low antitumor efficacy in vivo. One example is the 
targeted delivery of noscapine, an orally available plant-derived anti-tussive alkaloid which 
shows antitumor activity by targeting tubulin, however, related preclinical studies did not 
exhibit significant inhibition of tumor growth even using high dosage (450 mg/kg), which 
may result from the shorter circulation time and lower drug uptake by tumor cells. Abdalla 
et al (Abdalla, Karna et al. 2010) have developed uPAR-targeted IO nanoparticles for 
selective delivery of noscapine to prostate cancer by conjugating the human ATF to the IO 
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nanoparticles, and encapsulated about 80% of noscapine onto the uPAR-targeted 
nanoparticles via the interaction between the hydrophobic noscapine molecules and the 
hydrophobic segment of the amphiphilic polymer coating of nanoparticles. Their data 
showed the nanoparticles were uniformly sized and stable at physiological pH, while 
about 80% of drug molecules were efficiently released at pH 4 due to the onset of polymer 
degradation at lower pH, the breakage of hydrophobic interactions between polymer and 
drug molecules or hydrogen bonding. The hATF-Cy5.5-IO-Nos nanoparticles could 
significantly inhibit the proliferation of uPAR-positive human prostate carcinoma PC-3 cells 
compared with the nontargeted IO-Nos and free drug at the same concentration (10 μM). 
The uPAR-targeted NPs also delivered a significantly higher concentration of noscapine to 
the receptor positive cells, which led to a 6-fold enhancement in cell death compared to the 
free drug. 
 
 
 
Fig. 8. A, flowchart of the synthesis. B, nanodrug characterization. The nanodrug consisted 
of dextran-coated MNs triple labeled with Cy5.5 dye, EPPT peptides, and synthetic siRNA 
duplexes. C, gel electrophoresis showing dissociation of siRNAs from the nanoparticles 
under reducing conditions. D, representative precontrast and postcontrast T2-weighted 
images (top) and color-coded T2 maps (bottom) of tumor-bearing mice injected i.v. with 
MN-EPPT-siBIRC5 (10 mg/kg iron). The tumors (outlined) were characteristically bright  
(T2 long) before contrast. At 24 h after injection, there was a loss of signal intensity  
(T2 shortening) associated with the tumors, indicative of nanodrug accumulation. E, 
quantitative analysis of tumor T2 relaxation times. T2 map analysis revealed a marked 
shortening of tumor T2 relaxation times 24 h after nanodrug injection, indicating 
accumulation of MN-EPPT-siBIRC5.Reproduced with permission from Kumar, M., M. Yigit, 
et al. 2010 "Image-guided breast tumor therapy using a small interfering RNA nanodrug." 
Cancer Res 70(19): 7553-61. 
Although much progress has been made in the development of tumor-targeted IO 
nanoparticles for the delivery of anticancer agents, there are still many obstacles to be 
overcome. First, the conjugation process during the synthesis of nano-drugs may induce a 
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change in the chemical properties of the drugs or a loss in magnetization of the core 
magnetic material. Second, the drug loading efficiency is not high as expected for most 
nano-drugs. Third, controlling the drug release at the proper compartment within the tumor 
is still quite challenging, since most of the loaded drugs in nanoparticles release either 
prematurely or at a low rate from the nanoparticles. In this regard, novel strategies such as 
the development of magnetic IO nanoparticles for hyperthermia treatment and heating-
induced drug release are under investigation and are expected to provide solutions for 
future clinical applications. 
5. Conclusions and perspectives 
Intensive investigations and the development of magnetic IO nanoparticles in the past 
decade have led to the much better understanding of the biological significances and 
potential biomedical applications of IO nanoparticles and a wide range of novel IO 
nanoparticle constructs designed for tumor targeted imaging and drug delivery. However, 
when constructing magnetic nanoparticles for tumor imaging and drug delivery, there are 
several goals that remain challenging to achieve, such as 1) specific accumulation in the 
tumor but minimal uptake in normal tissue and organs by selecting ideal tumor-targeted 
ligands; 2) modification of the surface and control of the size and charge of nanoparticles for 
adequate delivery; 3) regulation of blood circulation time; 4) stability of IO 
nanotherapeutics; 5) construction of smart tumor-targeted IO nanoparticles such that loaded 
drugs release only within tumor cells.  
Recently, increasing concerns are focused on the safety of IO nanotherapeutic delivery 
systems. Although many animal studies have not shown visible toxicities, most of the 
available data come from mice with only a few studies conducted in rats, dogs and 
monkeys, and the sub-chronic and chronic toxicity studies for most IO nanoparticles have 
yet to be performed. Little is known about the long-term fate of IO nanoparticles and the 
pharmacokinetic/pharmacodynamic (PK/PD) changes in IO nanotherapeutics in vivo. The 
EPR effect constitutes only part of the drug targeting mechanism, and accumulating 
evidence has shown that tumor-targeted nanotherapeutics can internalize into tumor cells to 
a significantly higher concentration than their non-targeted counterparts. The majority of 
nanotherapeutic delivery systems are non-targeted, thus intensive studies using tumor-
targeted nanoparticles as drug delivery carriers are needed.  
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